Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDL NASDAQ:BCYC NASDAQ:CRNX NASDAQ:IONS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$11.08+5.4%$9.78$6.38▼$17.30$1.07B1.47986,045 shs993,392 shsBCYCBicycle Therapeutics$7.99-6.2%$8.01$6.10▼$28.67$590.04M1.44269,610 shs151,217 shsCRNXCrinetics Pharmaceuticals$27.84-2.6%$30.77$24.10▼$62.53$2.68B0.33767,621 shs891,936 shsIONSIonis Pharmaceuticals$43.03+0.1%$39.07$23.95▼$50.43$6.86B0.251.75 million shs2.32 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals+5.42%+0.45%+25.77%+27.50%-32.19%BCYCBicycle Therapeutics-6.22%-8.16%+7.39%-14.09%-67.13%CRNXCrinetics Pharmaceuticals-2.62%-10.16%-5.43%-17.54%-47.59%IONSIonis Pharmaceuticals+0.12%+1.87%-1.28%+31.27%-13.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals2.6715 of 5 stars3.52.00.00.03.41.70.6BCYCBicycle Therapeutics3.4282 of 5 stars3.44.00.00.02.44.20.6CRNXCrinetics Pharmaceuticals3.3272 of 5 stars3.40.00.03.72.22.50.0IONSIonis Pharmaceuticals4.5496 of 5 stars4.43.00.03.03.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.00Buy$18.3365.46% UpsideBCYCBicycle Therapeutics 2.70Moderate Buy$24.22203.16% UpsideCRNXCrinetics Pharmaceuticals 2.80Moderate Buy$69.50149.64% UpsideIONSIonis Pharmaceuticals 2.86Moderate Buy$59.3838.01% UpsideCurrent Analyst Ratings BreakdownLatest CRNX, IONS, AVDL, and BCYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025IONSIonis PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$60.00 ➝ $64.007/31/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $65.007/31/2025IONSIonis PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$55.00 ➝ $62.007/18/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$22.007/17/2025BCYCBicycle TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $25.007/10/2025CRNXCrinetics PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$36.007/1/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.006/27/2025CRNXCrinetics PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/12/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.005/20/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$194.45M5.51N/AN/A$0.77 per share14.39BCYCBicycle Therapeutics$35.28M15.68N/AN/A$11.48 per share0.70CRNXCrinetics Pharmaceuticals$1.04M2,506.40N/AN/A$14.29 per share1.95IONSIonis Pharmaceuticals$944.05M7.27N/AN/A$3.96 per share10.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A184.67N/A-13.58%-36.07%-16.30%8/7/2025 (Estimated)BCYCBicycle Therapeutics-$169.03M-$3.14N/AN/AN/A-790.07%-25.54%-21.23%8/5/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/7/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$1.84N/AN/AN/A-28.25%-45.29%-8.99%N/ALatest CRNX, IONS, AVDL, and BCYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02N/AN/AN/A$60.28 millionN/A8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13N/AN/AN/A$0.52 millionN/A8/5/2025Q2 2025BCYCBicycle Therapeutics-$0.95N/AN/AN/A$9.43 millionN/A7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19$0.70+$0.51$0.70$270.90 million$452.00 million5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ABCYCBicycle TherapeuticsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.732.33BCYCBicycle TherapeuticsN/A14.8614.86CRNXCrinetics PharmaceuticalsN/A22.5322.53IONSIonis Pharmaceuticals0.992.879.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%BCYCBicycle Therapeutics86.15%CRNXCrinetics Pharmaceuticals98.51%IONSIonis Pharmaceuticals93.86%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals5.20%BCYCBicycle Therapeutics22.90%CRNXCrinetics Pharmaceuticals4.60%IONSIonis Pharmaceuticals2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7096.74 million91.71 millionOptionableBCYCBicycle Therapeutics24069.25 million53.40 millionOptionableCRNXCrinetics Pharmaceuticals21093.63 million89.32 millionOptionableIONSIonis Pharmaceuticals1,069159.39 million155.02 millionOptionableCRNX, IONS, AVDL, and BCYC HeadlinesRecent News About These CompaniesInsider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Sells 2,432 Shares of Stock4 hours ago | insidertrades.comIonis Pharmaceuticals (NASDAQ:IONS) Given New $64.00 Price Target at Raymond James FinancialAugust 1 at 10:59 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Given New $65.00 Price Target at HC WainwrightAugust 1 at 9:32 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Morgan StanleyAugust 1 at 7:53 AM | marketbeat.comIonis (IONS) Q2 Revenue Soars 101%August 1 at 2:37 AM | theglobeandmail.comMorgan Stanley Upgrades Ionis Pharmaceuticals (IONS)August 1 at 2:37 AM | msn.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up After Strong EarningsJuly 31 at 10:36 AM | marketbeat.comIonis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 OutlookJuly 31 at 10:11 AM | zacks.comIonis reports second quarter 2025 financial results and highlights progress on key programsJuly 31 at 2:29 AM | cadillacnews.comCIonis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call TranscriptJuly 31 at 2:29 AM | seekingalpha.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up Following Better-Than-Expected EarningsJuly 31 at 2:07 AM | americanbankingnews.comIonis Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call PresentationJuly 30 at 4:42 PM | seekingalpha.comIonis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease DrugJuly 30 at 2:34 PM | benzinga.comHere's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 EarningsJuly 30 at 10:31 AM | zacks.comIonis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat EstimatesJuly 30 at 9:11 AM | zacks.comIonis Pharmaceuticals Q2 2025 Earnings PreviewJuly 29, 2025 | msn.comAn Overview of Ionis Pharmaceuticals's EarningsJuly 29, 2025 | benzinga.comIonis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines AgencyJuly 29, 2025 | msn.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by TD Asset Management IncJuly 29, 2025 | marketbeat.comPrivate Advisor Group LLC Decreases Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)July 28, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by ARK Investment Management LLCJuly 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Stocks to Buy Ahead of the Upcoming Earnings SeasonBy Chris Markoch | July 11, 2025View 3 Stocks to Buy Ahead of the Upcoming Earnings SeasonPelosi Makes Big Bet on Broadcom—Here’s Why It MattersBy Gabriel Osorio-Mazilli | July 15, 2025View Pelosi Makes Big Bet on Broadcom—Here’s Why It MattersAnalysts Are Upgrading These 3 Massive AI Stocks After EarningsBy Leo Miller | July 29, 2025View Analysts Are Upgrading These 3 Massive AI Stocks After EarningsSoundHound Rises as Short Sellers Exit and AI Demand GrowsBy Thomas Hughes | July 9, 2025View SoundHound Rises as Short Sellers Exit and AI Demand GrowsCRNX, IONS, AVDL, and BCYC Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$11.08 +0.57 (+5.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.02 -0.05 (-0.50%) As of 08/1/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Bicycle Therapeutics NASDAQ:BCYC$7.99 -0.53 (-6.22%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.00 +0.01 (+0.13%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Crinetics Pharmaceuticals NASDAQ:CRNX$27.84 -0.75 (-2.62%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$27.82 -0.02 (-0.05%) As of 08/1/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Ionis Pharmaceuticals NASDAQ:IONS$43.03 +0.05 (+0.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$42.98 -0.05 (-0.10%) As of 08/1/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
